Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses1

Linear carbohydrate-peptide constructs based on the 13 amino acid nonnatural pan DR epitope (PADRE) and carbohydrate B cell epitopes are demonstrated to be potent immunogens. These data support our belief that PADRE should be considered as an alternative to more complex carriers for use in prophylaxis and therapeutic vaccines. Two model carbohydrate-PADRE glycoconjugates were used to demonstrate that PADRE could effectively provide T cell help for carbohydrate-specific Ab responses. Conjugates of PADRE covalently linked to the human milk oligosaccharide, lacto-N-fucopentose II or a dodecasaccharide derived from Salmonella typhimurium O-Ag induced high titer IgG Ab responses in mice, which were comparable to glycoconjugates employing human serum albumin (HSA) as the carrier protein. Different adjuvants, in combination with PADRE conjugates, allowed for the modulation of the isotype profile with alum supporting an IgG1 profile; QS-21 an IgG2a, 2b profile, while an alum/QS-21 mixture generated a balanced IgG1/IgG2b isotype profile. As defined by binding to synthetic glycoconjugates, dodecasaccharide-specific Abs exhibited fine specificity similar to protective polyclonal Ab responses previously reported for dodecasaccharide-protein conjugates. The same Abs bound to intact S. typhimurium cells, suggesting that biologically relevant specificities were produced. The affinity of the dodecasaccharide-specific Abs was further shown to be comparable to that of a well-characterized, high affinity monoclonal anti-carbohydrate Ab recognizing the same epitope.

[1]  A. Lindberg,et al.  Glycoprotein conjugate vaccines. , 1999, Vaccine.

[2]  S. Hoffman,et al.  Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. , 1999, Vaccine.

[3]  R. Meloen,et al.  Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines. , 1998, Vaccine.

[4]  F. Marincola,et al.  Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Alessandro Sette,et al.  The optimization of helper T lymphocyte (HTL) function in vaccine development , 1998, Immunologic research.

[6]  S. Hoffman,et al.  Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. , 1997, Vaccine.

[7]  C. Partidos,et al.  Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus , 1995, Journal of virology.

[8]  J. Mekalanos,et al.  Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen , 1995, Infection and immunity.

[9]  C. Kensil,et al.  Structural and immunological characterization of the vaccine adjuvant QS-21. , 1995, Pharmaceutical biotechnology.

[10]  A. Vitiello,et al.  Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. , 1995, Pharmaceutical biotechnology.

[11]  A. Fattom,et al.  Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. , 1995, Vaccine.

[12]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[13]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[14]  A. Ragauskas,et al.  Molecular recognition of a Salmonella trisaccharide epitope by monoclonal antibody Se155-4. , 1994, Biochemistry.

[15]  S. Gangloff,et al.  Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes , 1994, Infection and Immunity.

[16]  T. Barington,et al.  Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine , 1994, Infection and immunity.

[17]  R. Hunter,et al.  Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. , 1993, Journal of immunology.

[18]  H. Snippe,et al.  Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus , 1993, Journal of virology.

[19]  S. Hoffman,et al.  Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites , 1993, Infection and immunity.

[20]  A. Lanzavecchia Identifying strategies for immune intervention. , 1993, Science.

[21]  I. Pastan,et al.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A , 1993, Infection and immunity.

[22]  D. Morrison,et al.  Bacterial Endotoxic Lipopolysaccharides , 1992 .

[23]  H. Caldwell,et al.  Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein , 1992, The Journal of experimental medicine.

[24]  J. Poolman,et al.  Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines , 1991, Infection and immunity.

[25]  J. H. van de Wijgert,et al.  Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution , 1991, Infection and immunity.

[26]  J. Poolman,et al.  A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. , 1991, Journal of immunology.

[27]  R. Arnon Synthetic peptides as the basis for vaccine design. , 1991, Molecular immunology.

[28]  J. Berzofsky Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. , 1991, Biotechnology therapeutics.

[29]  D. Kasper,et al.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of clinical investigation.

[30]  Milich Dr Synthetic peptides: prospects for vaccine development. , 1990 .

[31]  R. Schneerson,et al.  Polysaccharide-protein conjugates: a new generation of vaccines. , 1990, The Journal of infectious diseases.

[32]  D. Milich Synthetic peptides: prospects for vaccine development. , 1990, Seminars in immunology.

[33]  M. Mitchell,et al.  Synthetic immunogens constructed from T-cell and B-cell stimulating peptides (T:B chimeras): preferential stimulation of unique T- and B-cell specificities is influenced by immunogen configuration. , 1990, Cellular immunology.

[34]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[35]  R. Woods,et al.  Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine. , 1989, Advances in experimental medicine and biology.

[36]  A. Vink,et al.  Virally induced modulation of murine IgG antibody subclasses , 1988, The Journal of experimental medicine.

[37]  R. Lerner,et al.  Immune response to uncoupled peptides of foot-and-mouth disease virus. , 1987, Immunology.

[38]  B. Plikaytis,et al.  Pneumococcal vaccine efficacy in selected populations in the United States. , 1986, Annals of internal medicine.

[39]  C. Leclerc,et al.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. , 1985, Journal of immunology.

[40]  M. Meldal,et al.  Immunochemistry of SalmonellaO-antigens: Studies of Salmonella BO antigen epitopes by enzyme-linked immunosorbent inhibition assays , 1985 .

[41]  S. Michalek,et al.  Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. , 1984, Journal of Immunology.

[42]  B. M. Pinto,et al.  Preparation of glycoconjugates for use as artificial antigens: a simplified procedure. , 1983, Carbohydrate research.

[43]  S. Feig,et al.  Pneumococcal vaccination of recipients of bone marrow transplants. , 1983, Archives of internal medicine.

[44]  R. Lerner,et al.  Synthetic peptide immunogens as vaccines. , 1983, Annual review of microbiology.

[45]  D. Briles,et al.  Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae , 1981, Nature.

[46]  C. Lugowski,et al.  Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. , 1981, Journal of immunology.

[47]  M. H. da Silva,et al.  Trypanosoma cruzi: role of different antibody classes in protection against infection in the mouse. , 1981, Experimental parasitology.

[48]  A. Lindberg,et al.  Artificial Salmonella Vaccines: Salmonella typhimurium O-Antigen-Specific Oligosaccharide-Protein Conjugates Elicit Protective Antibodies in Rabbits and Mice , 1981, Infection and immunity.

[49]  A. Sutton,et al.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates , 1980, The Journal of experimental medicine.

[50]  B. Greenwood,et al.  IMPAIRMENT OF THE IMMUNE RESPONSE TO VACCINATION AFTER ACUTE MALARIA , 1978, The Lancet.

[51]  I. Weissman,et al.  Lymphoid tissue architecture. III. Germinal centers, T cells, and thymus-dependent vs thymus-independent antigens. , 1976, Advances in experimental medicine and biology.

[52]  I. Weissman,et al.  Lymphoid tissue architecture. II. Ontogeny of peripheral T and B cells in mice: evidence against Peyer's patches as the site of generation of B cells. , 1974, Journal of immunology.

[53]  H. Spiegelberg,et al.  Biological activities of immunoglobulins of different classes and subclasses. , 1974, Advances in immunology.

[54]  H. Nikaido,et al.  CHAPTER 4 – Isolation and Chemical and Immunological Characterization of Bacterial Lipopolysaccharides , 1971 .

[55]  J. Humphrey,et al.  STUDIES ON GLOBULIN AND ANTIBODY PRODUCTION IN MICE THYMECTOMIZED AT BIRTH. , 1964, Immunology.